FDA product code JBI: Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Catalase Inhibition
JBI is the FDA product code for glucose-6-phosphate dehydrogenase (erythrocytic), catalase inhibition. It is a Class II device, regulated under 21 CFR 864.7360 and reviewed by the Hematology panel. Devices under JBI reach the market by 510(k); FDA lists no cleared 510(k)s for it.
Classification
| Field | Value |
|---|---|
| Device name | Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Catalase Inhibition |
| Device class | Class II |
| Regulation | 21 CFR 864.7360 |
| Review panel | HE — Hematology |
| Medical specialty | Hematology |
| Premarket route | 510(k) |
| Third-party 510(k) review eligible | Yes |
Recalls for JBI devices
openFDA lists no recalls for product code JBI.
Frequently asked questions
What is FDA product code JBI?
JBI is the FDA product code for glucose-6-phosphate dehydrogenase (erythrocytic), catalase inhibition. It is a Class II device, regulated under 21 CFR 864.7360 and reviewed by the Hematology panel.
What device class is JBI?
Class II, regulation 21 CFR 864.7360. Typical premarket route: 510(k).
Next steps
- Run an FDA pathway report with predicate devices for product code JBI
- Run a recall and safety report across every JBI manufacturer
- Watch product code JBI for new clearances and recalls
Source: openFDA device classification, 510(k), PMA, De Novo and recall data (public domain). Review days run from FDA receipt to decision. Not regulatory advice.